Home » Topics » Dermatologic, BioWorld Science

Dermatologic, BioWorld Science
RSS

ISA-247 investigated for psoriasis in Canadian phase III study

Dec. 9, 2004

Hydrocortisone NO-releasing derivative shows greater antiinflammatory effects than parent compound

Dec. 3, 2004

Groundbreaking study to explore benefits of long-term pimecrolimus treatment

Dec. 1, 2004

Protalex pursues approval of PRTX-100 for pemphigus

Nov. 29, 2004

Non-approvable letter for Extina

Nov. 29, 2004

Cytochroma cleared to begin Canadian phase Ia study of CTA-018 for psoriasis

Nov. 25, 2004

SRP-299 discontinued for moderate to severe pediatric atopic dermatitis

Nov. 25, 2004

New formulations comprising epinastine

Nov. 25, 2004

Liarozole reported safe and effective in the treatment of ichthyosis and psoriasis

Nov. 24, 2004

Preclinical efficacy of rosiglitazone in reducing cutaneous inflammation in psoriasis

Nov. 23, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...